A Clinical Decision Aid for Diagnosing Transient Loss of Consciousness

Status Completed

Clinical Trial Summary

BACKGROUND: Transient loss of consciousness (TLOC) - defined as spontaneous disruption of consciousness not due to head trauma and with complete recovery - has a lifetime prevalence of 50%. It is one of the commonest neurological complaints in primary and emergency care. Over 90% of TLOC is due to either syncope, epilepsy or dissociative seizures (DS, also known as 'Psychogenic Nonepileptic Seizures'). The rapid and accurate distinction of these diagnoses is vital to allow appropriate further management but at least 20-30% of patients are not managed optimally or misdiagnosed. We have previously demonstrated that, in patients with established diagnoses of epilepsy, syncope, or DS, an automated classifier using only information from 36 questions based on patient experience and lay witness reports (the initial Paroxysmal Event Profile, iPEP) could accurately diagnose 86.0% of patients (with 100% sensitivity and 91.7% specificity for syncope) AIMS: To calibrate the iPEP for discrimination between syncope, epilepsy, and DS in patients newly presenting with TLOC, validate its performance in an independent sample, and to explore acceptability of the use of such a tool to people with TLOC and witnesses. METHODS: Nested qualitative-quantitative prospective single-centre development and validation of the iPEP in patients presenting to Emergency Departments, syncope or epilepsy clinics with first presentations of TLOC, with semi-structured interviews conducted with a purposive sample of participants from the quantitative study. The iPEP will be calibrated using a previously-described procedure for variable selection and training of Random Forest (RF) classifiers, and validated with assessment of overall classification accuracy, alongside sensitivity, specificity, positive and negative predictive values, and area under receiver-operating curve for each of the three target diagnoses. Performance will be evaluated against a benchmark set by results from previous research in patients with established diagnoses of epilepsy, syncope, and DS. OUTPUTS: Results will be submitted for publication in academic and professional literature. If performance from feasibility can be replicated in validation, the iPEP will be suitable to begin process of registration as a medical device for implementation in clinical pathways to minimise inappropriate referrals and treatment, streamline patient pathways, and enable earlier ordering of appropriate investigations to ensure prompt and appropriate diagnosis and management. If pilot performance could be replicated in this population and proportional savings from current estimated costs of misdiagnosis achieved, this could potentially save £63.9 million of annual UK healthcare expenditure.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05367999
Study type	Observational
Source	Sheffield Teaching Hospitals NHS Foundation Trust
Contact
Status	Completed
Phase
Start date	February 9, 2022
Completion date	June 30, 2023

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04534777` - Multimodal Neuroprognostication in Disorders of Consciousness
Completed	`NCT03504709` - REsting and Stimulus-based Paradigms to Detect Organized NetworkS and Predict Emergence of Consciousness
Recruiting	`NCT05823454` - Consciousness-specific Brain Network Connection of Propofol Sedation and Prolonged Disorders of Consciousness
Recruiting	`NCT04978857` - Feasibility Study of Virtual Reality to Promote the Awakening of Patients in a State of Minimal Consciousness	N/A
Not yet recruiting	`NCT05670873` - Transcranial Magnetic Stimulation in Disorder of Consciousness in Acute Severe Cerebrovascular Disease Patients	N/A
Terminated	`NCT03023657` - Detection of Arousal With Facial Micro-expression in Severe Brain-damaged Patient	N/A
Completed	`NCT04435301` - Oscillatory Acoustic-electric Stimulation in Patients With Disorders of Consciousness	N/A
Completed	`NCT05802524` - Neurophysiological Evaluation of Residual Cognitive Functions in Patients With Severe Alterations of Consciousness
Not yet recruiting	`NCT04248946` - Neural, Behavioural, and Clinical Effects of tDCS in PDOC; Feasibility Study	N/A
Completed	`NCT04476589` - Prognostication of Recovery in Early Disorders of Consciousness After COVID-19
Completed	`NCT04687397` - Behavioral Signs of Consciousness Recovery in Patients With Disorders of Consciousness (DOCSIGNS)
Recruiting	`NCT04411719` - Outcome Prediction in Patients With Acute Disorders of Consciousness
Recruiting	`NCT04065386` - Transcutaneous Auricular Vagal Nerve Stimulation for Post-coma Patients With Disorders of Consciousness	N/A
Completed	`NCT03341325` - Neurovascular Reactions to AAT in Patients With DOC	N/A
Withdrawn	`NCT03475537` - tDCS in Patients With Disorders of Consciousness	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.